Survivor (n = 56) | Non-survivor (n = 22) | P value | |
---|---|---|---|
Baseline characteristics | |||
Age (years) | 68 (59–76) | 72 (56–76) | 0.40 |
Male, no. (%) | 40 (71) | 17 (77) | 0.60 |
Body mass index (kg/m2) | 22 (19–26) | 21 (20–24) | 0.61 |
Comorbidity, no. | 0.97 | ||
Infection/Malignancy/CVD | 4/10/6 | 1/4/1 | |
HT, HL, DM/others/non | 19/14/3 | 8/7/1 | |
Diagnosis, no. (%) | |||
Interstitial lung disease | 32 (57) | 6 (27) | 0.024 |
Non- interstitial lung disease | 25 (42) | 18 (75) | |
Infection/malignancy/CVD/others, no. | 12/4/6/2 | 5/2/3/6 | |
Laboratory data on day of BAL | |||
White blood cell count (103/μL) | 8.8 (6.2–11) | 11 (5.9–14) | 0.15 |
Neutrophils (%) | 82 (72–91) | 84 (79–91) | 0.16 |
C-reactive protein (mg/dL) | 7.4 (2.3–17) | 10.6 (6.9–18) | 0.20 |
Lactate (mg/dL) | 1.1 (0.9–1.5) | 1.6 (1.0–2.3) | 0.11 |
PaO2/FiO2 ratio | 233 (183–279) | 201 (164–254) | 0.14 |
BAL findings | |||
MV or NIV at BAL, no. (%) | 13 (23) | 12 (55) | 0.014 |
Recovered BAL fluid (%) | 51 (30–61) | 43 (29–53) | 0.14 |
Total cell counts in BALF (104/mL) | 28 (17–46) | 30 (10–44) | 0.58 |
Fractionation in BALF (%) | |||
Macrophages | 38 (20–57) | 37 (16–60) | 0.87 |
Neutrophils | 12 (3.5–38) | 53 (12–72) | 0.0016 |
Lymphocytes | 30 (12–50) | 7.0 (2.9–13) | <0.0001 |
Eosinophils | 1.0 (0–2.0) | 0 (0–2.1) | 0.022 |
Treatments | |||
Methylprednisolone pulse, no. (%) | 32 (57) | 13 (59) | 1.00 |
Corticosteroids therapy, no. (%) | 45 (80) | 17 (77) | 0.76 |
Initial dose of corticosteroids (mg/kg) | 0.80 (0.46–1.0) | 0.98 (0.79–1.14) | 0.23 |
Outcome | |||
Length of hospital stay (days) | 30 (19–53) | 39 (18–96) | 0.28 |